Affiliation:
1. Department of Thoracic Oncology Kanagawa Cancer Center Yokohama Kanagawa Japan
2. Respiratory Disease Center Yokohama City University Medical Center Yokohama Kanagawa Japan
Abstract
AbstractAmong epidermal growth factor receptor (EGFR) mutation‐positive non‐small cell lung cancers, squamous cell carcinoma is less common and shows lower responsiveness to first‐generation EGFR tyrosine kinase inhibitors (TKIs) compared to adenocarcinoma. However, the efficacy of osimertinib for squamous cell carcinoma with EGFR mutations is not well known. This study reports the case of a 57‐year‐old male diagnosed as having stage IIIC squamous cell lung cancer. Oncomine Dx Target Test identified EGFR exon19 deletion and de novo EGFR T790M mutation with variant allele frequencies (VAF) of 21.6% and 25.2%, respectively. The patient was treated with osimertinib after progression on chemoradiotherapy followed by durvalumab, and a partial response was maintained for more than 20 months. To predict EGFR‐TKI efficacy, confirmation of gene mutations and VAF using next‐generation sequencing is helpful.
Subject
Pulmonary and Respiratory Medicine,Oncology,General Medicine
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献